In 1832, French chemist Michel Eugène Chevreul boiled down skeletal muscle and isolated a compound he named from the Greek ...
Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE studyPUL 2.0 year-over-year decline ...
New research finds that birds can use lactate, often thought of as a metabolic waste product, as a cellular fuel that aids in ...
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today ...
Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data from ...
In the Baby-COMET trial, Nexviazyme met all primary and secondary endpoints, teeing it up for potential label expansion.
TG Therapeutics, Inc. boosts anti-CD20 share as Q1 revenue jumps 69.6% to $204.9M, but overbought signals hint at a near-term ...
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in ...
All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition ...
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form ...
Sanofi has announced that positive results from the Baby-COMET phase 3, single-arm, open-label study demonstrated that Nexviazyme (avalglucosidase alfa) met its primary endpoint of proportion of ...
Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results